Zydus unit, Formycon AG partner for US, Canada cancer biosimilar FYB206

• Zydus Lifesciences' UAE unit partnered with Formycon AG to supply a cancer treatment biosimilar (FYB206, a Keytruda biosimilar) in the US and Canada.
• Formycon AG will develop, register, manufacture, and supply the product, while Zydus will commercialize it.
• This collaboration marks Zydus' entry into the North American biosimilar market with an immunotherapy product.
• The partnership aims to expand access to affordable oncology care and complements Zydus' acquisition of Agenus Inc.'s manufacturing facilities.

Why It Matters: Zydus's deal expands affordable cancer treatment options in US/Canada.